Skip to main content
. 2019 May 6;8:72. doi: 10.1186/s13756-019-0518-2

Table 3.

Cost-effectiveness of antibiotics for treatment of pneumonia patients

Treatment strategy Total cost (USD) Incremental cost (USD) Total LY LY saveda ICER per LY saved
Vancomycin 16,346 9.84
Teicoplanin 12,487 − 3858 10.80 0.96 Dominant
Linezolid 19,230 2884 11.16 1.32 2185

USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio

aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin